tech. enhancements -- half-life/stealthing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : tech. enhancements -- half-life/stealthing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (12)	10/9/2001 10:48:00 AM
From: keokalani'nui	Read Replies (1) of 53

Intranasal Calcitonin. (Unigene?) Unigene Reports Success of Nasal Calcitonin Clinical Study - Primary Marker of Bone Loss Reduced by Over 40% - FAIRFIELD, N.J., Oct. 9 /PRNewswire/ -- Unigene Laboratories, Inc. (OTC Bulletin Board: UGNE - news) today reported that the analysis of the data from the pivotal clinical trials for its proprietary nasal calcitonin spray showed a rapid and persistent reduction in bone loss as measured by several accepted blood markers. The results of this study will be presented on October 15th at the annual meeting of the American Society for Bone and Mineral Research in Phoenix, Arizona. A substance in the bloodstream which measures the rate of bone loss in the tested subjects decreased by an average of over 40% in the first month of the study, and that reduction was maintained throughout the three-month dosing period during which the measurements were taken. All other blood markers of bone loss that were measured showed significant decreases as well. The study was conducted with 134 osteoporotic women at five clinical centers in the U.S. and the United Kingdom.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next